Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort

被引:17
|
作者
Fainberg, Hernan P. [1 ]
Oldham, Justin M. [2 ]
Molyneaux, Philip L. [1 ,3 ,4 ]
Allen, Richard J. [5 ]
Kraven, Luke M. [5 ]
Fahy, William A. [6 ]
Porte, Joanne [7 ]
Braybrooke, Rebecca [7 ]
Saini, Gauri [7 ]
Karsdal, Morten A. [9 ]
Leeming, Diane J. [9 ]
Sand, Jannie M. B. [9 ]
Triguero, Isaac [8 ,10 ]
Oballa, Eunice [3 ,4 ,6 ]
Wells, Athol U. [1 ]
Renzoni, Elisabetta [1 ,3 ,4 ]
Wain, Louise, V [5 ,11 ]
Noth, Imre [12 ]
Maher, Toby M. [1 ,3 ,4 ,13 ]
Stewart, Iain D. [1 ]
Jenkins, R. Gisli [1 ,3 ,4 ]
机构
[1] Imperial Coll London, Natl Heart & Lung Inst, London, England
[2] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[3] Guys & St Thomas NHS Fdn Trust, Royal Brompton Hosp, London, England
[4] Guys & St Thomas NHS Fdn Trust, Harefield Hosp, London, England
[5] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England
[6] GlaxoSmithKline Med Res Ctr, Discovery Med, Stevenage, Herts, England
[7] NIHR Biomed Res Ctr, Nottingham Resp Res Unit, Nottingham, England
[8] Univ Nottingham, Sch Comp Sci, Computat Optimisat & Learning Lab, Nottingham, England
[9] Nordic Biosci, Herlev, Denmark
[10] Univ Granada, Andalusian Inst Data Sci AndComputat Intelligence, Granada, Spain
[11] Glenfield Hosp, Leicester Resp Biomed Res Ctr, Natl Inst Hlth Res, Leicester, Leics, England
[12] Univ Virginia, Pulm & Crit Care Med, Charlottesville, VA USA
[13] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
来源
LANCET DIGITAL HEALTH | 2022年 / 4卷 / 12期
基金
英国医学研究理事会;
关键词
PHASE-3; TRIAL; DOUBLE-BLIND; PIRFENIDONE; IPF; MORTALITY;
D O I
10.1016/S2589-7500(22)00173-X
中图分类号
R-058 [];
学科分类号
摘要
Background Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease with a variable clinical trajectory. Decline in forced vital capacity (FVC) is the main indicator of progression; however, missingness prevents long-term analysis of patterns in lung function. We aimed to identify distinct clusters of lung function trajectory among patients with idiopathic pulmonary fibrosis using machine learning techniques. Methods We did a secondary analysis of longitudinal data on FVC collected from a cohort of patients with idiopathic pulmonary fibrosis from the PROFILE study; a multicentre, prospective, observational cohort study. We evaluated the imputation performance of conventional and machine learning techniques to impute missing data and then analysed the fully imputed dataset by unsupervised clustering using self-organising maps. We compared anthropometric features, genomic associations, serum biomarkers, and clinical outcomes between clusters. We also performed a replication of the analysis on data from a cohort of patients with idiopathic pulmonary fibrosis from an independent dataset, obtained from the Chicago Consortium. Findings 415 (71%) of 581 participants recruited into the PROFILE study were eligible for further analysis. An unsupervised machine learning algorithm had the lowest imputation error among tested methods, and self-organising maps identified four distinct clusters (1-4), which was confirmed by sensitivity analysis. Cluster 1 comprised 140 (34%) participants and was associated with a disease trajectory showing a linear decline in FVC over 3 years. Cluster 2 comprised 100 (24%) participants and was associated with a trajectory showing an initial improvement in FVC before subsequently decreasing. Cluster 3 comprised 113 (27%) participants and was associated with a trajectory showing an initial decline in FVC before subsequent stabilisation. Cluster 4 comprised 62 (15%) participants and was associated with a trajectory showing stable lung function. Median survival was shortest in cluster 1 (2 center dot 87 years [IQR 2 center dot 29-3 center dot 40]) and cluster 3 (2 center dot 23 years [1 center dot 75-3 center dot 84]), followed by cluster 2 (4 center dot 74 years [3 center dot 96-5 center dot 73]), and was longest in cluster 4 (5 center dot 56 years [5 center dot 18-6 center dot 62]). Baseline FEV1 to FVC ratio and concentrations of the biomarker SP-D were significantly higher in clusters 1 and 3. Similar lung function clusters with some shared anthropometric features were identified in the replication cohort. Interpretation Using a data-driven unsupervised approach, we identified four clusters of lung function trajectory with distinct clinical and biochemical features. Enriching or stratifying longitudinal spirometric data into clusters might optimise evaluation of intervention efficacy during clinical trials and patient management. Copyright (c) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
引用
收藏
页码:E862 / E872
页数:11
相关论文
共 50 条
  • [41] Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP
    Costabel, Ulrich
    Albera, Carlo
    Kirchgaessler, Klaus-Uwe
    Gilberg, Frank
    Petzinger, Ute
    Noble, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [42] Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis
    Aono, Yuya
    Nakamura, Yutaro
    Kono, Masato
    Nakamura, Hidenori
    Yokomura, Koshi
    Imokawa, Shiro
    Toyoshima, Mikio
    Yasui, Hideki
    Hozumi, Hironao
    Karayama, Masato
    Suzuki, Yuzo
    Furuhashi, Kazuki
    Enomoto, Noriyuki
    Fujisawa, Tomoyuki
    Inui, Naoki
    Suda, Takafumi
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2020, 14
  • [43] Decline in forced vital capacity (FVC) in subjects with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) compared with healthy references
    Valenzuela, Claudia
    Bonella, Francesco
    Moor, Catharina C.
    Weimann, Gerrit
    Miede, Corinna
    Stowasser, Susanne
    Maher, Toby M.
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [44] Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis
    Biondini, Davide
    Balestro, Elisabetta
    Lacedonia, Donato
    Cerri, Stefania
    Milaneschi, Rosanna
    Luppi, Fabrizio
    Cocconcelli, Elisabetta
    Bazzan, Erica
    Clini, Enrico
    Barbaro, Maria Pia Foschino
    Gregori, Dario
    Cosio, Manuel G.
    Saetta, Marina
    Spagnolo, Paolo
    SCIENTIFIC REPORTS, 2018, 8
  • [45] A NEW METHOD TO EVALUATE THE CLINICAL EFFICACY OF PIRFENIDONE FOR PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS BY USING PERSONAL FORCED VITAL CAPACITY CHANGE
    Yamauchi, Hiroyoshi
    Bando, Masashi
    Ogura, Takashi
    Suda, Takafumi
    Taniguchi, Hiroyuki
    Mukae, Hiroshi
    Kishi, Kazuma
    Sugiyama, Yukihiko
    RESPIROLOGY, 2014, 19 : 151 - 151
  • [46] Validation of A 25-Gene Blood Transcriptomic Signature Predictive of Forced Vital Capacity Decline in Patients With Idiopathic Pulmonary Fibrosis
    Bonham, C.
    Neely, M. L.
    Huang, Y.
    Ma, S.
    Kim, J. S.
    Oldham, J. M.
    Becker, K.
    Soellner, J.
    Todd, J. L.
    Noth, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [47] Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis
    Davide Biondini
    Elisabetta Balestro
    Donato Lacedonia
    Stefania Cerri
    Rosanna Milaneschi
    Fabrizio Luppi
    Elisabetta Cocconcelli
    Erica Bazzan
    Enrico Clini
    Maria Pia Foschino Barbaro
    Dario Gregori
    Manuel G Cosio
    Marina Saetta
    Paolo Spagnolo
    Scientific Reports, 8
  • [48] The Burden and Impact of Cough in Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the Prospective Observational PROFILE Study
    Saunders, Peter
    Wu, Zhe
    Fahy, William A.
    Stewart, Iain D.
    Saini, Gauri
    Smith, David J. F.
    Braybrooke, Rebecca
    Stock, Carmel
    Renzoni, Elisabetta A.
    Johnson, Simon R.
    Jenkins, R. Gisli
    Belvisi, Maria G.
    Smith, Jaclyn A.
    Maher, Toby M.
    Molyneaux, Philip L.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2023, 20 (09) : 1267 - 1273
  • [49] Quartile Forced Vital Capacity Changes At 3, 6, 9, And 12 Months With Pirfenidone In Patients With Idiopathic Pulmonary Fibrosis: A Pooled Phase Iii Analysis
    Bonella, F.
    Sussman, R.
    Ettinger, N.
    Zisman, D.
    Trzaskoma, B. L.
    Chou, W.
    Kardatzke, D.
    Costabel, U.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [50] Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study
    Faverio, Paola
    Fumagalli, Alessia
    Conti, Sara
    Madotto, Fabiana
    Bini, Francesco
    Harari, Sergio
    Mondoni, Michele
    Oggionni, Tiberio
    Barisione, Emanuela
    Ceruti, Paolo
    Papetti, Maria Chiara
    Bodini, Bruno Dino
    Caminati, Antonella
    Valentino, Angela
    Centanni, Stefano
    Noe, Donatella
    Della Zoppa, Matteo
    Crotti, Silvia
    Grosso, Marco
    Sukkar, Samir Giuseppe
    Modina, Denise
    Andreoli, Marco
    Nicali, Roberta
    Suigo, Giulia
    De Giacomi, Federica
    Busnelli, Sara
    Cattaneo, Elena
    Mantovani, Lorenzo Giovanni
    Cesana, Giancarlo
    Pesci, Alberto
    Luppi, Fabrizio
    ERJ OPEN RESEARCH, 2022, 8 (01)